Vonoprazan Fumarate

富马酸沃诺拉赞

Vonoprazan Fumarate

V656608-1ml

1ml

10mM in DMSO

避光,干燥,-80℃储存

超低温冰袋运输

Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB) , with antisecretory activity. Vonoprazan Fumarate inhibits H + ,K + -ATPase activity in porcine gastric microsomes with an IC 50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease In Vitro Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H + ,K + -ATPase activity in a concentration-dependent manner. Vonoprazan does not inhibit Na + ,K + -ATPase activity, even at concentrations 500 times higher than their IC 50 values against gastric H + ,K + -ATPase activity. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male 7- or 8-week-old Sprague-Dawley ratDosage: 0.5, 1, 2, and 4 mg/kg Administration: Oral administration Result: Inhibited basal gastric acid secretion in a dose-dependent manner. IC50& Target:IC50: 19 nM (porcine gastric H + ,K + -ATPase, at pH 6.5)

富马酸伏诺普拉赞（TAK-438）是一种质子泵抑制剂（PPI），是一种强效口服活性钾竞争性酸阻滞剂（P-CAB），具有抗分泌活性。富马酸伏诺普拉赞能抑制猪胃微粒体中 H + 、K + -ATP 酶的活性，其作用机制如下

881681-01-2(DMSO)

C21H20FN3O6S

461.5 g/mol

CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=CC(=O)O)C(=O)O